Form 4: Iteos Therapeutics CFO Matthew Gall Granted Stock Options

Chief Financial Officer of Iteos Therapeutics, Matthew Gall, received stock options for 163,200 shares on March 7, 2024, vesting over four years.

Summary

• Matthew Gall, the Chief Financial Officer of Iteos Therapeutics, Inc., was granted stock options on March 7, 2024.
• The options are for 163,200 shares of common stock.
• The exercise price of the options is $11.58.
• The options vest over four years, with 25% vesting on March 7, 2025, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continued service to Iteos Therapeutics.
• The options expire on March 7, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to drive long-term value creation.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates